weight-loss drug

Stock futures indicate a dip due to geopolitical tensions, particularly the Iran conflict impacting oil and supply chains, and domestic policy debates concerning the Federal Reserve. Key developments include ongoing global instability, political scrutiny of the Fed, disruptions to helium and fertilizer supplies, Meta’s VR platform U-turn, and Novo Nordisk’s enhanced weight-loss drug approval, all influencing market sentiment and corporate strategies.

Amazon Pharmacy is expanding into the weight-loss drug market by offering Novo Nordisk’s oral Wegovy pill. This move increases patient access to the popular medication, previously dominated by injectables. Amazon aims to make treatment more accessible with pricing as low as $25 per month with insurance and $149 without. The integration with One Medical clinics further streamlines prescription fulfillment, highlighting Amazon’s growing presence in healthcare. This strategic expansion positions Amazon as a key player in reshaping weight management treatments.